levormeloxifene levormeloxifene levormeloxifene (inn; developmental code names 6720-cdri, nnc-460020) is a selective estrogen receptor modulator (serm) which was being developed as an alternative to estrogen replacement therapy for the treatment and prevention of postmenopausal bone loss but did not complete development and hence was never marketed. the development was stopped because of a high incidence of gynecological side effects during clinical trials. levormeloxifene is the levorotatory enantiomer of ormeloxifene, which, in contrast, has been marketed, though rather as a hormonal contraceptive. levormeloxifeneclinical dataother nameslevomeloxifene; 6720-cdri; nnc-460020identifiers iupac name 1-(2-phenoxy]ethyl)pyrrolidine cas number78994-23-7 npubchem cid35805chemspider32935 yunii9512ukz352chemblchembl301327 ycomptox dashboard (epa)dtxsid6046844 chemical and physical dataformulac30h35no3molar mass457.614 g·mol−13d model (jsmol)interactive image smiles o(c1ccc(cc1)3c4c(oc(3c2ccccc2)(c)c)cc(oc)cc4)ccn5cccc5 inchi inchi=1s/c30h35no3/c1-30(2)29(23-9-5-4-6-10-23)28(26-16-15-25(32-3)21-27(26)34-30)22-11-13-24(14-12-22)33-20-19-31-17-7-8-18-31/h4-6,9-16,21,28-29h,7-8,17-20h2,1-3h3/t28-,29+/m1/s1 ykey:xzeuaxywnkykpl-wdynhajcsa-n y ny (what is this?) (verify)